

Alfasigma: production plant in Sermoneta (Latina)

Today Alfasigma has three production sites in central-southern Italy: Alanno in Abruzzo, Pomezia and Sermoneta in Lazio. While the Alanno and Pomezia plants manufacture over-the-counter (OTC) and prescription drugs, the Sermoneta plant (Biosint S.p.A.) produces active pharmaceutical ingredients (APIs) and nutritional ingredients for the dietary supplement market, both in Italy and abroad. Located in the province of Latina, the Sermoneta plant employs over 100 people dedicated to production and related services. Besides the typical operations — synthesis, concentration, crystallisation, centrifugation, drying and packaging — the facilities at this chemical plant use techniques that are not readily seen at in other similar sites,



techniques such as the use of ion-exchange resins, nanofiltration and electrodialysis, even on a pilot scale.

History — The Sermoneta plant was founded in 1979 and, for over 40 years, has been a hub of chemical-pharmaceutical excellence within the area.

Dimensions — The plant consists of two adjacent production areas and covers a total area of 130,000 m², 18,000 m² of which are covered.

Production capacity — The site can produce about 260 tons per year, including the production of both active ingredients and nutritional ingredients.

Products and pharmaceutical forms – The plant manufactures active pharmaceutical ingredients and active ingredients for nutraceuticals in accordance with Good Manufacturing Practices (cGMP), with independent, fully dedicated production lines and departments.

The carnitine produced in this plant was the first to be registered as active pharmaceutical ingredient by over 30 Ministries of Health and the first to be approved by the FDA (the US body for the regulation of active ingredients and nutritional ingredients).



News and future developments — In the next few years, we intend to further develop and diversify activities so as to position the site as a production hub for the Italian and foreign pharmaceutical and nutraceutical industry: an industrial partner of excellence for the development and manufacture of high added value products with cutting edge technological content, capable of creating business models for the development and manufacture of APIs (active pharmaceutical ingredients) and nutraceutical products.

Marco Iorio is the Chief Executive Officer of Biosint S.p.A. With a degree in Law, he started working at Biosint in Human Resources in 1988, before taking on roles of increasing responsibility in Sigma-Tau Group companies, particularly in the Marketing and Supply Chain areas.

Before taking up his current role as CEO, he assumed the position of General Manager.

Media Relations

Biagio Oppi, Head of Corporate Communication & Media Relations.

Phone: +39 338 6352349 | Email: biagio.oppi@alfasigma.com

Corporate website (currently undergoing restructuring) is www.alfasigma.com

Adnkronos Communication

Phone: +39 06 5807501 | Email: comunicazione.media@adnkronos.com

Last update, June 2020.